8-K: Viridian Therapeutics Announces $300 Million At-the-Market Offering

Viridian Therapeutics enters into an agreement with Jefferies LLC for a potential $300 million at-the-market offering to fund clinical development and commercialization efforts.

Summary

• Viridian Therapeutics has entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell shares of its common stock, with an aggregate offering price of up to $300 million.
• The company intends to use the net proceeds from this offering to further the clinical development of its product candidates, prepare for commercialization of any product candidates that receive regulatory approval (including veligrotug), and for working capital and general corporate purposes.
• The shares will be offered and sold through Jefferies LLC, acting as a sales agent.
• Jefferies will be entitled to a commission of up to 3.0% of the gross proceeds of shares sold.
• The company is not obligated to sell any shares and may suspend sales at any time.
• Concurrently with this agreement, Viridian Therapeutics terminated its previous Open Market Sale Agreement from September 9, 2022, which had an aggregate offering price of up to $175 million, under which the company had sold $115.2 million of shares.
• No further offerings or sales of common stock will be conducted under the prior agreement.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. While it provides Viridian with access to capital, it also introduces potential dilution for existing shareholders. The success of the offering will depend on market conditions and investor confidence in the company's prospects.

Positives

• The potential $300 million in funding could significantly boost Viridian Therapeutics' ability to advance its clinical programs and prepare for commercialization.
• The at-the-market offering provides flexibility, allowing the company to sell shares based on market conditions.
• The termination of the prior sales agreement simplifies the company's capital structure.

Negatives

• The offering could dilute existing shareholders' equity.
• There is no guarantee that the company will be able to sell all $300 million worth of shares.
• The company will incur commissions and other expenses related to the offering, reducing the net proceeds.

Risks

• Market conditions may not be favorable for selling shares at desired prices.
• Clinical trials may not be successful, impacting the value of the company and its stock.
• Regulatory approvals for product candidates may not be obtained, hindering commercialization efforts.
• The company may not be able to effectively compete in the market.

Future Outlook

Viridian Therapeutics intends to use the proceeds from the offering to advance its clinical programs, prepare for commercialization, and for general corporate purposes. The company has the flexibility to sell shares based on market conditions, but there is no guarantee that the full $300 million will be raised.

Industry Context

At-the-market offerings are a common financing strategy for biotech companies, providing a flexible way to raise capital without a traditional underwritten offering. This allows companies to take advantage of favorable market conditions and fund ongoing research and development activities.

Comparison to Industry Standards

• Comparable companies such as Horizon Therapeutics and Global Blood Therapeutics have utilized ATM offerings to fund clinical trials and commercial expansion.
• The commission rate of 3.0% is within the typical range for ATM offerings in the biotech industry.
• The size of the offering, $300 million, is significant and reflects Viridian's need for capital to support its pipeline.

Stakeholder Impact

• Shareholders may experience dilution of their ownership stake.
• Employees may benefit from increased funding for research and development.
• Customers may benefit from the potential commercialization of new therapies.
• The company's financial position may be strengthened, benefiting creditors.

Next Steps

• Viridian Therapeutics will offer shares of common stock through Jefferies LLC as sales agent.
• Jefferies LLC will use commercially reasonable efforts to sell the shares from time to time, based upon the company's instructions.
• The company may suspend sales under the Sale Agreement at any time.
• The company will file prospectus supplements with the SEC in connection with the offering.

Key Dates

Keywords

at-the-market offering, common stock, Jefferies LLC, clinical development, commercialization, veligrotug, Viridian Therapeutics, financing